A5080835325- Botulinum Toxin and Related Neurological Disorders
- Cerebral Palsy and Movement Disorders
- Stroke Rehabilitation and Recovery
- Neurological disorders and treatments
- Medical and Biological Ozone Research
- Long-Term Effects of COVID-19
- Cancer Treatment and Pharmacology
- Muscle Physiology and Disorders
Ministry of Health of the Russian Federation
2024
Russian Medical Academy of Continuous Professional Education
2016
Spasticity treatment is one of the key aspects contemporary cerebral palsy (CP) rehabilitation that influences on effectiveness other methods. The paper presents first Russian document unites recommendations for BTA CP and could be used as guideline multilevel injections. consensus botulinum toxin A (BTA) spastic based international data results national studies. authors describe typical spasticity patterns in upper lower extremities, give recommended intervals (Abobotulinum A) dosages whole...
научный биометрический журнал, который знакомит читателя с клиническими рекомендациями и особенностями применения лекарственных вакцинных средств у детей, предоставляет исчерпывающую информацию о воздействии на плод, проводимых в
One of the modern components complex rehabilitation patients with spasticity is use botulinum toxin type A (BTA) preparations. International experience therapy in children spans more than 30 years. Abobotulinum has been used to treat since 1994. Clinical studies have shown high efficacy abobotulinumtoxin relieving lower and upper extremities cerebral palsy (CP) other disorders, which associated a significant increase muscle tone, thereby increasing motor skills achieving individual patient...
There are still no guidlines on managment of Duchenne/Becker myodystrophy in domestic medical practice. It leads to decrease quality of life and, what is more important, lifespan patients. In this article we have described our Western coleagues lаst decade experience, including consensus guidelines published 2010 mаnаgment Duchenne myodystrophy, supplemented with practicle experience. We have standardized motor development scale and muscle tone score for patients MDD/MDB, algorithm...
Botulinum neurotoxin type-A (BoNT-A) has been used in association with other interventions the management of spasticity children cerebral palsy (CP) for almost two decades. This article is based on review International Consensus statements 2006, 2009 and 2010. In algorithm botulinum toxin therapy goals determination, list necessary assessment scales protocols injected muscles determination have described. Attention paid to randomized clinical trials, possible complications method perspectives.